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Objective: Hyperbaric oxygen therapy (HBOT) for refractory late radiation cystitis has been reported 
with success rates of 60% to 92%. HORTIS (Hyperbaric Oxygen Radiation Tissue Injury Study) is a 
multicenter study conducted by the Baromedical Research Foundation, South Carolina, USA. 
Tygerberg Hospital and University of Stellenbosch is one of 6 centers recruiting patients for the 
radiation cystitis arm (HORTIS-III).  
Methods: Patients were prospectively randomized: Group A (treatment) received HBOT (100% 
oxygen at 2.0 atmospheres). Group B (control) received sham treatment (21% oxygen at 1.0 
atmosphere). Patients and referring physicians were blinded to the randomization process. Patients 
received 30-40 sessions of either HBOT or sham treatment. After unblinding, patients in the control 
group were offered crossover to the treatment group. Primary outcome measures included clinical 
evaluation, SOMALENT and EPIC scores. 
Results: In total, 34 patients were screened, 5 met the inclusion and exclusion criteria and agreed to 
participate. Two patients were randomized to Group A. One patient received 30 sessions of HBOT. 
One patient absconded after 26 sessions of HBOT. Three patients were randomized to Group B and 
received 40 sessions of sham treatment. All 3 control patients elected to cross over: two patients 
completed 40 sessions of HBOT, one stopped at 24 sessions due to an unrelated medical condition 
(critical limb ischemia). No serious adverse events occurred. At 14 months follow-up after HBOT, 3 
patients showed improvement in SOMALENT and EPIC scores. One patient with a vesicovaginal 
fistula showed complete radiographic resolution at 14 months follow-up. In total, 13 patients have 
been recruited internationally. 
Conclusion: HBOT remains a treatment option for refractory late radiation cystitis. The evidence 
presented is inconclusive due to the low number of patients, but the ongoing multicenter trial is 
expected to provide conclusive evidence.  
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